TrialSignal transduction and targeted therapy2026

PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure.

Wei Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.